Communiqués X4 Pharmaceuticals, Inc.

Actions

XFOR

US98420X2027

Produits pharmaceutiques

Temps réel estimé Cboe BZX 16:26:45 23/09/2026			Varia. 5j.	Varia. 1 janv.
3,285 ^USD	-4,23%		-6,55%	-18,00%

08/09	X4 Pharmaceuticals conclut un accord avec la FDA sur l'essai de Phase 3 révisé pour son traitement de la neutropénie chronique	MT
08/09	X4 Pharmaceuticals annonce une issue favorable suite à sa réunion de type C avec la FDA et fait le point sur l'essai de phase 3 4WARD dans la neutropénie chronique	CI

Communiqués

09/09	X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference	AQ
08/09	X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting	AQ
01/09	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
06/08	X4 Pharmaceuticals: Q2 Earnings Snapshot	AQ
06/08	X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
03/08	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
07/07	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
01/07	X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors	AQ
01/06	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
27/05	X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference	AQ
06/05	X4 Pharmaceuticals: Q1 Earnings Snapshot	AQ
06/05	X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update	AQ
29/04	X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union	AQ
01/04	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
17/03	X4 Pharmaceuticals: Q4 Earnings Snapshot	AQ
17/03	X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update	AQ
04/03	X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference	AQ
02/03	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
02/03	X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome	AQ
27/02	X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome	GL
03/02	X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026	GL
02/02	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
05/11	X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference	GL
05/11	X4 Pharmaceuticals: Q3 Earnings Snapshot	AQ
05/11	X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update	GL